{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:53Z","timestamp":1794047453301,"version":"4.8.0"},"reference-count":49,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>While novel radioisotope therapies continue to advance cancer care, reports of therapy-related myeloid neoplasms (t-MN) have generated concern. The prevalence and role of clonal hematopoiesis (CH) in this process remain to be defined. We hypothesized that: (i) CH is prevalent in relapsed follicular lymphoma and is associated with t-MN transformation, and (ii) radiation in the form of radioimmunotherapy (RIT) plays a role in clonal progression. In this retrospective cohort study, we evaluated the prevalence and prognostic impact of CH on clinical outcomes in 58 heavily pre-treated follicular lymphoma patients who received RIT. Patients had been given a median of four lines of therapy before RIT. The prevalence of CH prior to RIT was 46%, while it was 67% (P=0.15) during the course of RIT and subsequent therapies in the paired samples. Fourteen (24%) patients developed t-MN. Patients with t-MN had a higher variant allele fraction (38% vs. 15%; P=0.02) and clonal complexity (P=0.03) than those without. The spectrum of CH differed from that in age-related CH, with a high prevalence of DNA damage repair and response pathway mutations, absence of spliceosome mutations, and a paucity of signaling mutations. While there were no clear clinical associations between RIT and t-MN, or overall survival, patients with t-MN had a higher mutant clonal burden, along with extensive chromosomal abnormalities (median survival, afer t-MN diagnosis, 0.9 months). The baseline prevalence of CH was high, with an increase in prevalence on exposure to RIT and subsequent therapies. The high rates of t-MN with marked clonal complexities and extensive chromosomal damage underscore the importance of better identifying and studying genotoxic stressors accentuated by therapeutic modalities.<\/jats:p>","DOI":"10.3324\/haematol.2023.283727","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T16:12:32Z","timestamp":1693411952000},"page":"509-520","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic relevance of clonal hematopoiesis in myeloid neoplastic transformation in patients with follicular lymphoma treated with radioimmunotherapy"],"prefix":"10.3324","volume":"109","author":[{"given":"Zhuoer","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra","family":"Lasho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Finke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun Vinod","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"57378","doi-asserted-by":"crossref","unstructured":"Saiki R, Momozawa Y, Nannya Y. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis. Nat Med. 2021; 27(7):1239-1249.","DOI":"10.1038\/s41591-021-01411-9"},{"key":"57379","doi-asserted-by":"crossref","unstructured":"Jacobs KB, Yeager M, Zhou W. Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet. 2012; 44(6):651-658.","DOI":"10.1038\/ng.2270"},{"key":"57380","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Fontanillas P, Flannick J. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498.","DOI":"10.1056\/NEJMoa1408617"},{"key":"57381","doi-asserted-by":"crossref","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-2487.","DOI":"10.1056\/NEJMoa1409405"},{"key":"57382","doi-asserted-by":"crossref","unstructured":"Fabre MA, de Almeida JG, Fiorillo E. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022; 606(7913):335-342.","DOI":"10.1038\/s41586-022-04785-z"},{"key":"57383","doi-asserted-by":"crossref","unstructured":"Coombs CC, Zehir A, Devlin SM. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017; 21(3):374-382.","DOI":"10.1016\/j.stem.2017.07.010"},{"key":"57384","doi-asserted-by":"crossref","unstructured":"Voso MT, Falconi G, Fabiani E. What\u2019s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood. 2021; 138(9):749-757.","DOI":"10.1182\/blood.2021010764"},{"key":"57385","doi-asserted-by":"crossref","unstructured":"Bolton KL, Ptashkin RN, Gao T. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020; 52(11):1219-1226.","DOI":"10.1038\/s41588-020-00710-0"},{"key":"57386","doi-asserted-by":"crossref","unstructured":"Gillis NK, Ball M, Zhang Q. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017; 18(1):112-121.","DOI":"10.1016\/S1470-2045(16)30627-1"},{"key":"57387","doi-asserted-by":"crossref","unstructured":"Wong TN, Ramsingh G, Young AL. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015; 518(7540):552-555.","DOI":"10.1038\/nature13968"},{"key":"57388","doi-asserted-by":"crossref","unstructured":"Hsu JI, Dayaram T, Tovy A. PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell. 2018; 23(5):700-713.","DOI":"10.1016\/j.stem.2018.10.004"},{"key":"57389","doi-asserted-by":"crossref","unstructured":"Takahashi K, Wang F, Kantarjian H. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017; 18(1):100-111.","DOI":"10.1016\/S1470-2045(16)30626-X"},{"key":"57390","doi-asserted-by":"crossref","unstructured":"Gibson CJ, Lindsley RC, Tchekmedyian V. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017; 35(14):1598-1605.","DOI":"10.1200\/JCO.2016.71.6712"},{"key":"57391","doi-asserted-by":"crossref","unstructured":"Husby S, Favero F, Nielsen C. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. Leukemia. 2020; 34(12):3256-3268.","DOI":"10.1038\/s41375-020-0795-z"},{"key":"57392","doi-asserted-by":"crossref","unstructured":"Wong TN, Miller CA, Jotte MRM. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nat Commun. 2018; 9(1):455.","DOI":"10.1038\/s41467-018-02858-0"},{"key":"57393","doi-asserted-by":"crossref","unstructured":"Miller PG, Sperling AS, Brea EJ. Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. Blood Adv. 2021; 5(15):2982-2986.","DOI":"10.1182\/bloodadvances.2021004554"},{"key":"57394","doi-asserted-by":"crossref","unstructured":"Saini NY, Swoboda DM, Greenbaum U. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov. 2022; 3(5):385-393.","DOI":"10.1158\/2643-3230.BCD-21-0177"},{"key":"57395","doi-asserted-by":"crossref","unstructured":"Singh A, Mencia-Trinchant N, Griffiths EA. Mutant PPM1D-and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy. JCO Precis Oncol. 2022; 6:e2100309.","DOI":"10.1200\/PO.21.00309"},{"key":"57396","doi-asserted-by":"crossref","unstructured":"Puvvada SD, Guill\u00e9n-Rodr\u00edguez JM, Yan J. Yttrium-90-ibritumomab tiuxetan (Zevalin\u00ae) radioimmunotherapy after cytoreduction with ESHAP chemotherapy in patients with relapsed follicular non-Hodgkin lymphoma: final results of a phase II study. Oncology. 2018; 94(5):274-280.","DOI":"10.1159\/000486788"},{"key":"57397","doi-asserted-by":"crossref","unstructured":"Alcindor T, Witzig TE. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin\u2019s lymphoma. Curr Treat Options Oncol. 2002; 3(4):275-282.","DOI":"10.1007\/s11864-002-0027-y"},{"key":"57398","doi-asserted-by":"crossref","unstructured":"Strosberg J, El-Haddad G, Wolin E. Phase 3 trial of 177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376(2):125-135.","DOI":"10.1056\/NEJMoa1607427"},{"key":"57399","doi-asserted-by":"crossref","unstructured":"Sartor O, de Bono J, Chi KN. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021; 385(12):1091-1103.","DOI":"10.1056\/NEJMoa2107322"},{"key":"57400","doi-asserted-by":"crossref","unstructured":"Jacobs SA, Swerdlow SH, Kant J. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008; 14(21):7088-7094.","DOI":"10.1158\/1078-0432.CCR-08-0529"},{"key":"57401","doi-asserted-by":"crossref","unstructured":"Scholz CW, Pinto A, Linkesch W. 90Yttrium-ibritumomabtiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013; 31(3):308-313.","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"57402","doi-asserted-by":"crossref","unstructured":"Morschhauser F, Radford J, van Hoof A. 90Yttriumibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013; 31(16):1977-1983.","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"57403","doi-asserted-by":"crossref","unstructured":"Illidge TM, Mayes S, Pettengell R. Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF\/BNLI criteria. J Clin Oncol. 2014; 32(3):212-218.","DOI":"10.1200\/JCO.2013.50.3110"},{"key":"57404","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Tuck M, Estes J. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results. Blood. 2009; 114(22):3759-3759.","DOI":"10.1182\/blood.V114.22.3759.3759"},{"key":"57405","doi-asserted-by":"crossref","unstructured":"Press OW, Unger JM, Rimsza LM. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013; 31(3):314-320.","DOI":"10.1200\/JCO.2012.42.4101"},{"key":"57406","doi-asserted-by":"crossref","unstructured":"Bennett JM, Kaminski MS, Leonard JP. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005; 105(12):4576-4582.","DOI":"10.1182\/blood-2004-12-4690"},{"key":"57407","doi-asserted-by":"crossref","unstructured":"Pritzl SL, Gurney M, Badar T. Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis - a prospective Mayo clinic cohort study. Leuk Res. 2023; 125:107007.","DOI":"10.1016\/j.leukres.2022.107007"},{"key":"57408","doi-asserted-by":"crossref","unstructured":"Kumar E, Okosun J. Follicular lymphoma genomics. Hemasphere. 2019; 3(Suppl):79-81.","DOI":"10.1097\/HS9.0000000000000213"},{"key":"57409","doi-asserted-by":"crossref","unstructured":"Niroula A, Sekar A, Murakami MA. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021; 27(11):1921-1927.","DOI":"10.1038\/s41591-021-01521-4"},{"key":"57410","doi-asserted-by":"crossref","unstructured":"Zhou X, Edmonson MN, Wilkinson MR. Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat Genet. 2016; 48(1):4-6.","DOI":"10.1038\/ng.3466"},{"key":"57411","doi-asserted-by":"crossref","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e8res H. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016; 91(11):1096-1101.","DOI":"10.1002\/ajh.24492"},{"key":"57412","doi-asserted-by":"crossref","unstructured":"Grillo-L\u00f3pez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther. 2002; 2(5):485-493.","DOI":"10.1586\/14737140.2.5.485"},{"key":"57413","doi-asserted-by":"crossref","unstructured":"Radivoyevitch T, Sachs RK, Gale RP. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia. 2015; 30(2):285-294.","DOI":"10.1038\/leu.2015.258"},{"key":"57414","doi-asserted-by":"crossref","unstructured":"Czuczman MS, Emmanouilides C, Darif M. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007; 25(27):4285-4292.","DOI":"10.1200\/JCO.2006.09.2882"},{"key":"57415","doi-asserted-by":"crossref","unstructured":"Reiss J, Link B, Ruan J. Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leuk Lymphoma. 2015; 56(10):2870-2875.","DOI":"10.3109\/10428194.2015.1016929"},{"key":"57416","doi-asserted-by":"crossref","unstructured":"McNerney ME, Godley LA, le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017; 17(9):513.","DOI":"10.1038\/nrc.2017.60"},{"key":"57417","doi-asserted-by":"crossref","unstructured":"Teipel R, Kroschinsky F, Kramer M. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022; 6(6):1941-1946.","DOI":"10.1182\/bloodadvances.2021005747"},{"key":"57418","doi-asserted-by":"crossref","unstructured":"Gibson CJ, Lindsley RC, Tchekmedyian V. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017; 35(14):1598-1605.","DOI":"10.1200\/JCO.2016.71.6712"},{"key":"57419","doi-asserted-by":"crossref","unstructured":"Teipel R, Kroschinsky F, Kramer M. Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment. Blood Adv. 2022; 6(6):1941-1946.","DOI":"10.1182\/bloodadvances.2021005747"},{"key":"57420","doi-asserted-by":"crossref","unstructured":"Mouhieddine TH, Sperling AS, Redd R. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020; 11(1):2996.","DOI":"10.1038\/s41467-020-16805-5"},{"key":"57421","doi-asserted-by":"crossref","unstructured":"Ortmann CA, Dorsheimer L, Abou-El-Ardat K. Functional dominance of CHIP-mutated hematopoietic stem cells in patients undergoing autologous transplantation. Cell Rep. 2019; 27(7):2022-2028.","DOI":"10.1016\/j.celrep.2019.04.064"},{"key":"57422","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei A, Niederwieser D. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"57423","doi-asserted-by":"crossref","unstructured":"Chantadisai M, Kulkarni HR, Baum RP. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. Eur J Nucl Med Mol Imaging. 2021; 48(5):1390-1398.","DOI":"10.1007\/s00259-020-05127-9"},{"key":"57424","doi-asserted-by":"crossref","unstructured":"Kesavan M, Claringbold PG, Turner JH. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology. 2014; 99(2):108-117.","DOI":"10.1159\/000362558"},{"key":"57425","unstructured":"FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. 2022."},{"key":"57426","doi-asserted-by":"crossref","unstructured":"Morice PM, Leary A, Dolladille C. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021; 8(2):e122-e134.","DOI":"10.1016\/S2352-3026(20)30360-4"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283727\/76028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283727\/76542","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11249\/76028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:47Z","timestamp":1794045887000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283727","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}